文献速递脑血管病

血液生物标志物在缺血性卒中预后中的作用:系统综述

Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis: A Systematic Review.
PubMed 文献 · Stroke · 2021-01-12

结果显示利钠肽、炎症、动脉粥样硬化和应激反应相关标志物最有前景,但研究方法学缺陷常见且异质性大。

要点

  • 利钠肽、炎症及应激反应标志物与缺血性卒中不良预后最一致相关。
  • 多数研究调整了卒中严重程度和年龄,但仅少数报告校准和重分类指标。
  • 研究间异质性大,无法进行荟萃分析,方法学缺陷仍普遍。

核心结论

  • 利钠肽及炎症、动脉粥样硬化和应激反应标志物是缺血性卒中预后最有前景的血液生物标志物。
  • 尽管样本量增加,方法学缺陷仍常见,研究间高度异质性妨碍了荟萃分析。

研究设计与样本

  • 纳入标准为缺血性卒中后7天内测量血液生物标志物并报告至少7天后的功能结局或死亡。
  • 中位样本量为232(四分位距110-455)。

主要发现

  • 260篇(89%)文章报告回归分析,其中78%调整卒中严重程度,82%调整年龄,67%同时调整两者,9%均未调整。
  • 37%的研究调查区分度,5%调查校准度,11%调查重分类。
  • 利钠肽、和肽素、降钙素原、甘露糖结合凝集素、脂肪细胞脂肪酸结合蛋白和皮质醇在较高质量研究中与不良预后最一致相关,并显示对既定预后因素的增量价值。

关键数值与推荐

  • 利钠肽、炎症、动脉粥样硬化和应激反应标志物被确定为最有前景的预后生物标志物。
  • 其他生物标志物与不良预后的关联较不一致或来自较低质量研究。

临床怎么用

  • 临床可考虑检测利钠肽及炎症、应激反应相关标志物以辅助缺血性卒中预后评估。
  • 需注意现有研究方法学异质性大,标志物的增量预后价值尚需更高质量研究验证。

局限性

  • 研究间高度异质性,无法进行荟萃分析。
  • 方法学缺陷仍常见,仅少数研究报告校准度和重分类指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Outcome prognostication in ischemic stroke patients remains challenging due to limited predictive properties of existing models. Blood-based biomarkers might provide additional information to established prognostic factors. We intended to identify the most promising prognostic biomarkers in ischemic stroke, their incremental prognostic value, and whether their predictive value differs among etiologies. METHODS: We searched MEDLINE (Ovid) and Institute for Scientific Information Web of Knowledge for articles reporting the predictive performance of blood-based biomarkers measured up to 7 days after ischemic stroke and reporting functional outcome or death at least 7 days after stroke. This work updates a previous systematic review (up to January 2007), follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and was registered (International Prospective Register of Systematic Reviews PROSPERO 2018; https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42018094671). RESULTS: Two hundred ninety-one articles published between January 2007 and August 2018 comprising 257 different biomarkers met inclusion criteria. Median sample size was 232 (interquartile range, 110-455); 260 (89%) articles reported regression analyses with 78% adjusting for stroke severity, 82% for age, 67% for both, and 9% for none of them; 37% investigated discrimination, 5% calibration, and 11% reclassification. Including publications from a previous systematic review (1960-January 2007), natriuretic peptides, copeptin, procalcitonin, mannose-binding lectin, adipocyte fatty acid-binding protein, and cortisol were the biomarkers most consistently associated with poor outcome in higher-quality studies showing an incremental value over established prognostic factors. Other biomarkers were less consistently associated with poor outcome or were reported in lower quality studies. High heterogeneity among studies precluded the performance of a meta-analysis. CONCLUSIONS: The number of reports on prognostic blood-based biomarkers in ischemic stroke increased 3.5-fold in the period January 2007 to August 2018. Although sample size increased, methodological flaws are still common. Natriuretic peptides and markers of inflammation, atherogenesis, and stress response are the most promising prognostic biomarkers among identified studies.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Montellano FA, Ungethüm K, Ramiro L, et al. Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis: A Systematic Review. Stroke. 2021. PMID: 33430636. doi:10.1161/STROKEAHA.120.029232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。